A quarterly analytical discussion on study startup
The ChromoReport is a quarterly analytical discussion on study startup utilizing anonymized aggregated clinical data from leading Pharmas and CROs, representing over 70 percent of clinical trial sites engaged in phase II & III studies.
To centralize SSU or not? In a recently completed comprehensive study conducted by Tufts Center for the Study of Drug Development (CSDD), Start-up Time And Readiness Tracking (START) II, 2017, concluded that there was no conclusive evidence that centralizing the function of site identification through to activation achieved significant improvements in terms of cycle time reductions. Irrespective of organizational structure both groups face similar challenges and see the same opportunities for improvement.
But what do the industry metrics have to say about cycle time performance of multi-country vs. single country studies?
Download the September 2017 edition of the ChromoReport today! Fill out the form to get your copy.